Incentive Spirometry in Routine Management of COPD Patients

Menoufia University40 enrolled

Overview

The incentive spirometer is a device that encourages patients, with visual and other positive feedback, to maximally inflate their lungs and sustain that inflation. However, its efficacy in patients with COPD has been little documented especially in diaphragmatic function. This study tried to assess the role of incentive spirometry on Spirometric functions, Sonographic diaphragmatic function, and the scale of dyspnea in COPD patients with exacerbation and with follow-up of these parameters after 2 months.

Forty COPD patients were admitted with an acute exacerbation and the patients were divided randomly into 2 equal groups: the first used the incentive spirometer together with medical treatment (according to GOLD guidelines) for 2 months and the second received only medical treatment for 2 months. All participants, on admission, underwent assessment of mMRC dyspnea scale, spirometry, arterial blood gases, and diaphragmatic ultrasound. Then, a follow-up of the participants was done after 2 months with the same parameters and a comparison between both groups was done.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

COPD

Interventions

incentive spirometryDEVICE

It is flow-oriented that has 3 chambers, (600, 900, and 1200 cc/s) and it has a mouthpiece and a ball in each chamber. After a quiet exhalation, each participant was instructed to take slow full inspirations and to keep as long as he can for at least 5 seconds, then he slowly expires. The device is used every hour at least 5 to 10 times in the session during wake time.

Eligibility

Sex: ALLMin age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * confirmed cases of COPD according to the criteria GOLD * age more than 40 years Exclusion Criteria: * bad acoustic window by ultrasound * other chronic respiratory diseases * lung malignancy * recent major surgery * inability to complete or perform the study * patient refusal

Locations (1)

Amal A. El-Koa

Cairo, Egypt

Outcomes

Primary Outcomes

assessing the change in baseline diaphragmatic excursion in cm

assessing the change from Baseline diaphragmatic excursion (in cm) using ultrasound to 2 months

Time frame: 2 months

assessing the change in baseline percentage of diaphragmatic thickness fraction

assessing the change from baseline percentage of diaphragmatic thickness fraction (%) using ultrasound to 2 months

Time frame: 2 months

assessing the change in baseline forced vital capacity percentage of predicted

assessing the change from baseline forced vital capacity percentage of predicted (%) using spirometry to 2 months

Time frame: 2 months

assessing the change in baseline forced expiratory volume in 1st second/forced vital capacity percentage (%)

assessing the change from baseline forced expiratory volume in 1st second/forced vital capacity percentage (%) using spirometry to 2 months

Time frame: 2 months

assessing the change in baseline peak expiratory flow rate percentage

assessing the change from baseline peak expiratory flow rate percentage (%) using spirometry to 2 months

Time frame: 2 months

change in arterial blood gases

assessment the change in baseline PaO2 and PaCO2 (in mmHg) to 2 months

Time frame: 2 months

assessing the change in mMRC dysnea scale

assessing the change in the severity of dyspnea by mMRC dysnea scale from baseline to 2 months. It is 5 statements giving grades from 0 to 4 with the higher the degree, the more severe the shortness of breath in patients with COPD

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.